Publicacións en colaboración con investigadores/as de Hannover Medical School (2)

2023

  1. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

    Blood, Vol. 141, Núm. 2, pp. 156-167

2009

  1. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older

    Blood, Vol. 114, Núm. 6, pp. 1166-1173